Cobimetinib
- Generic Name
- Cobimetinib
- Brand Names
- Cotellic
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21F3IN3O2
- CAS Number
- 934660-93-2
- Unique Ingredient Identifier
- ER29L26N1X
- Background
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metasta...
- Indication
Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.
- Associated Conditions
- Histiocytic Neoplasm, Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CobimetinibProcedure: Computed TomographyProcedure: Diagnostic ImagingProcedure: I-131 Uptake TestRadiation: Iodine I-131Procedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyBiological: Recombinant Thyrotropin AlfaProcedure: Ultrasound ImagingDrug: Vemurafenib
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT06440850
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT05768178
- Locations
- 🇬🇧
Freeman Hospital, Newcastle, United Kingdom
🇬🇧Southampton General Hospital, Southampton, United Kingdom
🇬🇧Leeds General Infirmary, Leeds, United Kingdom
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
- Conditions
- Advanced Endometrial CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaMetastatic Endometrial CarcinomaMetastatic Platinum-Resistant Ovarian CarcinomaRecurrent Endometrial CarcinomaStage IV Uterine Corpus Cancer AJCC v8Metastatic Fallopian Tube CarcinomaMetastatic Primary Peritoneal CarcinomaRecurrent Fallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05691504
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT05441514
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05260684
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Drug: AlectinibDrug: AlpelisibDrug: AnastrozoleBiological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CapecitabineDrug: CarboplatinDrug: CobimetinibDrug: EntrectinibDrug: EribulinDrug: FulvestrantBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabDrug: IrinotecanDrug: LetrozoleDrug: Nab-paclitaxelDrug: NiraparibDrug: OlaparibDrug: PaclitaxelDrug: PalbociclibBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab EmtansineDrug: VemurafenibDrug: VinorelbineDrug: Vismodegib
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05159245
- Locations
- 🇫🇮
Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland
🇫🇮Kuopio University Hospital, Kuopio, Finland
🇫🇮Oulu University Hospital OYS Cancer Center, Oulu, Finland
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT05034627
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
- Conditions
- Metastatic Distal Bile Duct AdenocarcinomaUnresectable Liver CarcinomaMetastatic Gallbladder CarcinomaRecurrent Distal Bile Duct AdenocarcinomaMetastatic Intrahepatic CholangiocarcinomaRecurrent Gallbladder CarcinomaRecurrent Intrahepatic CholangiocarcinomaStage IV Distal Bile Duct Cancer AJCC v8Stage IV Gallbladder Cancer AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT04941287
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.